Welcome to our dedicated page for Sana Biotechnology news (Ticker: SANA), a resource for investors and traders seeking the latest updates and insights on Sana Biotechnology stock.
Sana Biotechnology, Inc. develops engineered cells as medicines for patients, with programs that apply cell engineering, hypoimmune platform technology, and fusogen-based delivery. News about SANA commonly covers its type 1 diabetes cell-replacement work, including UP421 and SC451, and its in vivo CAR T program SG293 for CD19-directed therapy in B-cell cancers and B-cell-mediated autoimmune diseases.
Company updates also include preclinical and clinical data presentations, research collaborations, manufacturing and regulatory preparation, financial results, equity financing activity, executive appointments, and investor conference presentations.
Sana Biotechnology, Inc. (SANA) has announced the pricing of its upsized initial public offering (IPO) of 23,500,000 shares at $25.00 per share, aiming for gross proceeds of $587.5 million. The IPO is set to trade on the Nasdaq Global Select Market starting February 4, 2021, with the offering closing on February 8, 2021. Additionally, underwriters have a 30-day option to purchase up to 3,525,000 shares, potentially increasing proceeds to approximately $675.6 million. Major banks involved include Morgan Stanley and Goldman Sachs.